Watchlist Idee ProPicks IA Filtro Ricerca dati Grafici Lavoro salvato

Alteogen Inc

KOSDAQ:A196170

Corea del Sud / Sanità / Biotecnologia

Panoramica

Cronol. dati finanziari 10 anni

Prezzo azione

371.500,00 KRW


Key Metrics	Latest
Total Revenue	102,9 B
Adjusted EBITDA	28,254 B
EBITDA Margin	27,5%
Net Profit Margin	58,9%
Total Assets	409 B
Total Debt	11,759 B

10Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending										Latest
(in millions)	Dec-15	Dec-16	Dec-17	Dec-18	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	12 Months

Revenue	4,727	6,844	12,104	13,703	29,229	42,426	38,746	28,806	96,523	102,855	102,855
% Growth		44.8%	76.9%	13.2%	113.3%	45.1%	-8.7%	-25.7%	235.1%	6.6%

Adjusted EBITDA	338	(5,059)	(5,750)	(7,107)	(1,280)	1,811	(13,041)	(26,719)	(6,403)	28,254	28,254
% Margin	7.1%	-73.9%	-47.5%	-51.9%	-4.4%	4.3%	-33.7%	-92.8%	-6.6%	27.5%	27.5%

Adjusted EBIT	124	(5,411)	(6,173)	(7,660)	(2,252)	(58)	(15,192)	(29,374)	(9,737)	25,404	25,404
% Margin	2.6%	-79.1%	-51.0%	-55.9%	-7.7%	-0.1%	-39.2%	-102.0%	-10.1%	24.7%	24.7%

Adjusted Net Income	1,208	(3,620)	(6,298)	(7,094)	(1,770)	(18,239)	(20,294)	(18,398)	(3,670)	60,569	60,569
% Margin	25.6%	-52.9%	-52.0%	-51.8%	-6.1%	-43.0%	-52.4%	-63.9%	-3.8%	58.9%	58.9%

Adjusted Basic EPS	28.59	(83.49)	(140.19)	(156.01)	(36.73)	(362.31)	(400.97)	(358.75)	(71.05)	1,140.33	1,140.33

Calcoli supportati

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
											Original
KRW	Fiscal Year Ending										Latest
(in millions)	Dec-15	Dec-16	Dec-17	Dec-18	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	Dec-24
	FY - 9	FY - 8	FY - 7	FY - 6	FY - 5	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM

Revenue	4,727	6,844	12,104	13,703	29,229	42,426	38,746	28,806	96,523	102,855	102,855
% Growth	NA	44.8%	76.9%	13.2%	113.3%	45.1%	-8.7%	-25.7%	235.1%	6.6%

Cost of Revenue	(1,273)	(6,233)	(11,103)	(11,870)	(18,215)	(23,748)	(33,045)	(24,352)	(65,382)	(38,813)	(38,813)
Gross Profit	3,454	611	1,001	1,833	11,015	18,678	5,701	4,454	31,141	64,041	64,041
% Revenue	73.1%	8.9%	8.3%	13.4%	37.7%	44.0%	14.7%	15.5%	32.3%	62.3%	62.3%

Research and Development	(1,947)	(3,976)	(4,654)	(5,962)	(6,457)	(7,691)	(7,480)	(18,660)	(25,306)	(24,550)	(24,550)
Selling and Marketing	(242)	(415)	(473)	(487)	(1,045)	(1,697)	(1,493)	(1,829)	(1,971)	(2,660)	(2,660)
General and Admin	(1,092)	(1,465)	(1,843)	(2,868)	(5,374)	(8,840)	(11,220)	(12,406)	(12,497)	(10,088)	(10,088)
Other Inc / (Exp)	231	208	(1,923)	632	(551)	(18,246)	2,337	15,026	441	2,725	2,725
Total Operating Exp	(3,050)	(5,648)	(8,893)	(8,685)	(13,426)	(36,474)	(17,856)	(17,868)	(39,333)	(34,574)	(34,574)

Operating Income	404	(5,037)	(7,892)	(6,851)	(2,412)	(17,796)	(12,155)	(13,413)	(8,192)	29,468	29,468
% Revenue	8.5%	-73.6%	-65.2%	-50.0%	-8.3%	-41.9%	-31.4%	-46.6%	-8.5%	28.6%	28.6%

Interest Expense	642	581	520	818	731	105	1,461	3,443	4,627	7,144	7,144
Pre-tax Income	1,047	(4,456)	(7,372)	(6,033)	(1,681)	(17,692)	(10,694)	(9,970)	(3,564)	36,612	36,612
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0	0	0	0
Provision for Taxes	162	869	(77)	(1,037)	(58)	(583)	(893)	(108)	(18)	24,078	24,078
Net Income to Company	1,208	(3,587)	(7,449)	(7,070)	(1,738)	(18,275)	(11,588)	(10,078)	(3,582)	60,690	60,690
% Margin	25.6%	-52.4%	-61.5%	-51.6%	-5.9%	-43.1%	-29.9%	-35.0%	-3.7%	59.0%	59.0%

Minority Interest in Earnings	0	0	0	198	1,034	2,453	5,313	1,932	210	1,562	1,562
Net Income to Stockholders	1,208	(3,587)	(7,449)	(6,872)	(705)	(15,822)	(6,275)	(8,146)	(3,372)	62,252	62,252

Preferred Dividends	0	0	0	0	0	0	0	0	0	0	0
Other Adj.	0	0	0	0	0	0	0	0	0	0	0

Net Income to Common	1,208	(3,587)	(7,449)	(6,872)	(705)	(15,822)	(6,275)	(8,146)	(3,372)	62,252	62,252
% Margin	25.6%	-52.4%	-61.5%	-50.2%	-2.4%	-37.3%	-16.2%	-28.3%	-3.5%	60.5%	60.5%

As Reported
Basic EPS (Continuing Ops)	28.59	(82.73)	(165.81)	(151.13)	(14.62)	(314.29)	(123.98)	(158.85)	(65.27)	1,172.04	1,172.04
Diluted EPS (Continuing Ops)	27.69	(82.78)	(165.83)	(151.13)	(14.62)	(314.29)	(124.00)	(159.00)	(65.27)	1,163.00	1,163.00

WA Basic Shares Out.	42.26	43.36	44.92	45.47	48.19	50.34	50.61	51.28	51.66	53.11	53.11
WA Diluted Shares Out.	43.89	43.36	44.92	45.47	48.19	50.34	50.61	51.28	51.66	53.11	53.11

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	1,047	(4,456)	(7,372)	(6,033)	(1,681)	(17,692)	(10,694)	(9,970)	(3,564)	36,612	36,612
Addback: Net Interest Expense	(642)	(581)	(520)	(818)	(731)	(105)	(1,461)	(3,443)	(4,627)	(7,144)	(7,144)
Addback: Other Non Operating Expenses, Total	(280)	(329)	163	(776)	202	17,690	8,729	(4,718)	(1,426)	(3,899)	(3,899)
Addback: Depreciation & Amortization	214	352	423	553	972	1,869	2,151	2,654	3,334	2,850	2,850
Addback: Restructuring Charges	0	0	0	0	0	0	0	0	0	0	0
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	0	0	0	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	0	0	(2)	(2)	0	0	(13,310)	(11,360)	(31)	(25)	(25)
Addback: Gain (Loss) On Sale Of Assets	0	15	(2)	(21)	(43)	81	18	(127)	(110)	0	0
Addback: Asset Writedown	0	0	1,559	3	0	10	1,525	528	22	15	15
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	0	(60)	0	(12)	0	(42)	0	(283)	0	(155)	(155)
Adjusted EBITDA	338	(5,059)	(5,750)	(7,107)	(1,280)	1,811	(13,041)	(26,719)	(6,403)	28,254	28,254
% Margin	7.1%	-73.9%	-47.5%	-51.9%	-4.4%	4.3%	-33.7%	-92.8%	-6.6%	27.5%	27.5%

Adjusted EBIT	124	(5,411)	(6,173)	(7,660)	(2,252)	(58)	(15,192)	(29,374)	(9,737)	25,404	25,404
% Margin	2.6%	-79.1%	-51.0%	-55.9%	-7.7%	-0.1%	-39.2%	-102.0%	-10.1%	24.7%	24.7%

Adjusted Net Income Reconciliation
Net Income to Company	1,208	(3,587)	(7,449)	(7,070)	(1,738)	(18,275)	(11,588)	(10,078)	(3,582)	60,690	60,690
Addback: Unusual Items	0	(44)	1,555	(33)	(43)	48	(11,766)	(11,243)	(119)	(165)	(165)
Less: Tax Benefit of Unusual Items (26%)	0	12	(404)	8	11	(13)	3,059	2,923	31	43	43
Adjusted Net Income	1,208	(3,620)	(6,298)	(7,094)	(1,770)	(18,239)	(20,294)	(18,398)	(3,670)	60,569	60,569
% Margin	25.6%	-52.9%	-52.0%	-51.8%	-6.1%	-43.0%	-52.4%	-63.9%	-3.8%	58.9%	58.9%

Errore di caricamento

Alteogen Inc

KOSDAQ:A196170

Corea del Sud / Sanità / Biotecnologia

Cronol. dati finanziari 10 anni